CraniUS Therapeutics Secures Significant Funding
Enabling Direct Therapeutic Access Beyond the Blood-Brain Barrier
CraniUS Therapeutics LLC, a pioneering neurotechnology firm, has successfully raised $20 million in a Series B financing round aimed at advancing its innovative NeuroPASS™ platform. This technology is designed to transcend the blood-brain barrier (BBB), which has long posed challenges for effective drug delivery and monitoring within the brain.
NeuroPASS™ is envisioned as a versatile platform comprising an extensive roadmap that includes three complementary products. These devices will transition cranial implants from being mere passive reconstructive hardware to active therapeutic interfaces, designed to facilitate long-term outpatient care for neurological patients.
The brainchild of Dr. Chad Gordon, a distinguished neuroplastic surgeon from Johns Hopkins, CraniUS Therapeutics was founded in response to a pressing clinical need. Dr. Gordon's extensive research over 15 years underscored the temporal cranial space as an optimal site for drug delivery, particularly for patients who suffer from severe neurological afflictions. Many patients do not benefit from surgical interventions simply because essential medicinal therapies fail to penetrate the BBB.
Reflecting on this challenge, Dr. Gordon expressed, "This is not an incremental advance—it represents a fundamentally new approach to treating neurological disease and brain cancer. We set out to build a platform that could help address a therapeutic barrier that has limited care for decades." His vision has become a critical mission for CraniUS Therapeutics.
The recent Series B financing comes on the heels of an earlier $20 million Series A round completed in 2022. The latest round includes $19 million from private investors and $1 million from non-dilutive funding provided by the state. To date, CraniUS has successfully raised around $40 million, which is set to bolster company operations well into the future.
The new funds will be channeled into various essential areas, including regulatory submissions, production scale-up, and product testing to ensure that NeuroPASS™ progresses towards eventual commercialization. This strategic expansion comes at a crucial time, as the demand for innovative solutions in neurology continues to rise.
CraniUS Therapeutics boasts an impressive portfolio of 15 domestic patents supporting its advanced platform along with numerous international patents. These intellectual properties are instrumental in establishing the company as a leader in neurosurgery and drug delivery innovation.
"Having led significant academic health systems and positioned myself at the nexus of care delivery and innovation, we have accomplished much in the medical field. Yet, the blood-brain barrier has defiantly resisted over a century's worth of pharmaceutical and medical device innovation," noted Dr. Stephen Klasko, a board member of CraniUS Therapeutics, highlighting the importance of the NeuroPASS™ initiative. "This strategy epitomizes transformative thinking in medicine, not just improvements but a total reconfiguration of how we gain access to the brain."
About CraniUS Therapeutics
CraniUS Therapeutics is committed to reshaping the neurotechnology landscape by developing the first fully implantable platform capable of bypassing the blood-brain barrier to facilitate long-term and programmable drug delivery. Their flagship device, NeuroPASS™, aims to radically alter treatment approaches for severe neurological conditions across various diseases using the temporal skull space. This Baltimore-based company collaborates with top-tier experts globally in the domains of neurosurgery, drug administration, implant design, and device engineering.
Frequently Asked Questions
What is the purpose of the NeuroPASS™ platform?
The NeuroPASS™ platform aims to bypass the blood-brain barrier to enhance drug delivery and monitoring capabilities within the brain, improving treatment outcomes for neurological patients.
Who founded CraniUS Therapeutics?
CraniUS Therapeutics was founded by Dr. Chad Gordon, a neuroplastic surgeon known for his innovative approaches to neurosurgery and therapeutic delivery.
How much funding did CraniUS raise in its Series B round?
CraniUS Therapeutics raised $20 million in its Series B financing round to support the development of its NeuroPASS™ platform.
What will the new capital be used for?
The new funds will be used for regulatory submissions, scaling up manufacturing, and testing of new products to facilitate commercialization.
What is the innovation behind NeuroPASS™?
NeuroPASS™ represents a fundamental shift in addressing the blood-brain barrier, aiming to provide targeted therapeutic access that has been elusive for decades.
